LinkedIn YouTube Bluesky
Search
English / Français
Ethics Portal
  • Who We Are
      • Who We Are
      • About Us
      • Business Model
      • Our Strategy 2023-2025
      • Statutes, By-Laws & Policies
      • Governance & Team
      • Annual Reports
  • What We Do
      • What We Do
      • Licensing for Public Health
      • mRNA Technology Transfer Hub Programme
      • Disease Areas
      • Addressing Children’s Needs
      • Prioritising Medicines for Licensing
      • Long-Acting Therapeutics
      • Focus areas
      • Biotherapeutics
      • Local and Regional Manufacturing
      • Pandemic Preparedness and Response
      • Upstream Access
      • Technology Transfer
      • Addressing Children's Needs
      • Patent Information Tools
      • MedsPaL
      • LAPaL
  • Progress
      • Progress
      • Licences
      • Prioritisation
      • Agreements with Innovators
      • Access to Medicines Tracker
      • Contribution to Universal Health Coverage
      • Endorsements
      • Impact
  • News & Publications
      • News
        & Publications
      • News, Events & Press Releases
      • Messages from the Executive Director
      • MPP in the Media
      • MPP Publications
      • Related Publications
      • Newsletters & Updates
  • Partners
      • Partners
      • Partnering with MPP
      • Funders
      • Our Stories
      • Voices from Friends of MPP
      • I am part of the DTG story
  • Contact Us
English / Français
Ethics Portal
Search

Stories

“Almost everyone now wants dolutegravir, but we are trying to make this transition period gradual ... and people are very much looking forward to receiving TLD, the once-daily pill containing dolutegravir”

people » Stories

Aibar Sultangaziev

22 March 2020

MPP Logo
  • About Us
  • MedsPaL
  • Careers & RFPs
  • Privacy Policy
Follow us
LinkedIn YouTube Bluesky

Founded & funded by

Unitaid Logo

Other funders

Designed and built by ACW